Home/Pipeline/Vyxeos

Vyxeos

Acute Myeloid Leukemia

CommercialMarketed

Key Facts

Indication
Acute Myeloid Leukemia
Phase
Commercial
Status
Marketed
Company

About Jazz Pharmaceuticals

Jazz Pharmaceuticals (NASDAQ: JAZZ) is a Dublin-based global biopharmaceutical company focused on transforming the lives of patients with rare diseases through innovative therapeutics. With a proven track record in developing and commercializing treatments for rare epilepsies, oncology, and sleep disorders, the company operates across nearly 100 countries with manufacturing facilities in the U.S., U.K., Ireland, and throughout Europe. Led by President and CEO Renee Gala, Jazz combines a patient-focused approach with science-driven research to advance a robust pipeline of innovative therapeutics targeting unmet medical needs.

View full company profile

Other Acute Myeloid Leukemia Drugs

DrugCompanyPhase
VANFLYTA (quizartinib)Daiichi SankyoApproved
ASP2215 (gilteritinib)Astellas PharmaApproved
KT-253Kymera TherapeuticsPhase 1